AVE 5883

Drug Profile

AVE 5883

Alternative Names: AVE-5883

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator Aventis Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 20 Jun 2006 Data presented at the 102nd International Conference of the American Thoracic Society (ATS-2006) have been added to the Obstructive Airways Disease therapeutic trials section
  • 29 Sep 2004 Phase-I/II clinical trials in Asthma in USA (Inhalation)
  • 29 Sep 2004 Phase-I/II clinical trials in Asthma in Netherlands (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top